Studies have shown that GRh2 can inhibit radiotherapy-induced NF-κB activity and PD-1 receptor expression by suppressing the MAPK pathway in a CT26/luc mouse colon cancer cell model, and GRh2 combined with radiotherapy treatment significantly slowed tumor growth and overall survival, inhibited tumor progression, and improved therapeutic effects (21). Here, NFKB1 is linked to neoplasm.